NCT03603808 2025-07-16
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
AIDS Malignancy Consortium
Phase 2 Completed
Clinical Trials
8 trialsNCT03721978 2024-10-17
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Inovio Pharmaceuticals
Phase 3 Completed
NCT03180684 2023-08-25
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Inovio Pharmaceuticals
Phase 2 Completed
NCT03185013 2023-07-27
REVEAL 1
Inovio Pharmaceuticals
Phase 3 Completed
NCT03499795 2023-07-14
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Inovio Pharmaceuticals
Phase 2 Completed
NCT02163057 2021-01-22
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Phase 1/2 Completed
NCT01188850 2018-08-10
Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
Inovio Pharmaceuticals
Phase 1 Completed
NCT00685412 2017-09-13
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
Inovio Pharmaceuticals
Phase 1 Completed